150
Participants
Start Date
January 8, 2018
Primary Completion Date
February 17, 2020
Study Completion Date
February 17, 2020
Rheosorbilact®
Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
Ringer lactate
Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
"Unimedi Adjara LLC", Batumi
JSC EVEX Medical corporation/Kutaisi Referral Hospital, Kutaisi
"Israel Georgian Medical Research Clinic HELSI Core LLC LTD.", Tbilisi
Hospital of the Medical Center Office of the President's Affairs Republic of Kazakhstan, Astana
"Municipal Clinical Hospital Sfinta Treime", Chisinau
Municipal Clinical Hospital, Chisinau
National institute of phthisiology and pulmonology named after F.G. Yanovsky NAMS of Ukraine, Kyiv
City Hospital №1, Mykolayiv
Vinnitsa National Medical University; City Clinical Hospital №1, Vinnitsa
Republican Scientific Center of Emergency Medical Aid, Tashkent
198 Hospital, Hanoi
Thai Binh University of Medicine and Pharmacy, Thái Bình
Yuria-Pharm
INDUSTRY